Monique Verhaegen, PhD

Research Investigator

Selected Publications

1. Bortolin S, Christopoulos TK, Verhaegen M. (1996) Quantitative Polymerase Chain Reaction Using a Recombinant DNA Internal Standard and Time-Resolved Fluorometry. Anal. Chem. 68: 834-840.
2. Verhaegen M, Iannou P, Christopoulos TK. (1998) Quantification of Prostate Specific Antigen and mRNA by Co-amplification with a Recombinant RNA Internal Standard and Microtiter Well-Based Hybridization. Clin. Chem. 44: 1170-1176.
3. Verhaegen M, Christopoulos TK. (1998) Quantitative Polymerase Chain Reaction Based on a Dual-Analyte Chemiluminescent Hybridization Assay for Target DNA and Internal Standard. Anal. Chem.70: 4120-4125.
4. Verhaegen M, Christopoulos TK. (2002) Bacterial Expression of In Vivo Biotinylated Aequorin and Application to Bioluminometric Hybridization Assays. Anal. Biochem. 306:314-22.
5. Verhaegen M, Christopoulos TK. (2002) Recombinant Gaussia Luciferase. Overexpression, Purification, and Analytical Application of a New Reporter for DNA Hybridization. Anal. Chem. 74: 4378-85.
6. Tannous B, Verhaegen M, Christopoulos TK. (2003) Combined Flash- and Glow-Type Chemiluminescent Reactions for High-Throughput Genotyping of Biallelic Polymorphisms. Anal. Biochem. 320: 266-272.
7. Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AW, Lowe SW, Soengas MS. (2005) Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic Implications. Cancer Res. 65(14): 6294-6304.
8. Pilon-Thomas S, Verhaegen M, Kuhn L, Riker A, Mule JJ. (2006) Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells. Cancer Immunol Immunother. 55(10):1238-46.
9. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR, Pointer JN, Gruber SB, Su LD, Nikiforov MA, Kaufman RJ, Bastian BC, Soengas MS. (2006) Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol. 8(10):1053-63.
10. Konopleva M, Contractor R, Tsao T, Ruvolo PP, Samudio I, Kitada S, Deng X, Zhai D, Yuexi S, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar, T., Ling X, Marini F, Harris D, Dietrich M., Estrov Z, McCubrey J, May WS, Reed JC, and Andreeff M. (2006) Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 10(5):375-388.
11. Verhaegen M, Bauer JA, Martin de la Vega C, Wang G, Wolter KG, Brenner JC, Nikolovska-Coleska Z, Bengtson A, Nair R, Elder JT, Carey TE, Bradford CR, Wang S, Soengas MS. (2006) A novel BH3 mimetic reveals a MAPK-dependent mechanism of melanoma cell survival controlled by p53 and reactive oxygen species. Cancer Res. 66(23):11348-359.
12. *Wolter KG, *Verhaegen M, Fernandez Y, Nikolovska-Coleska A, Bengtson A, Wang S. and Soengas MS. Selective killing of melanoma by exploiting differential requirements and regulation of Bcl-2 proteins following proteasomal inhibition. [Accepted in Cell Death and Differentiation, 2007]; *authors contributed equally
13. Kaneko T, Mantellini MG, Tatiana M, Botero TM, Karl E, Zeitlin B, Verhaegen M, Soengas MS, Linge M, Nunez G, and Nör JE. Neovascular endothelial cells regulate tumour cell phenotype. [Submitted to EMBO J]
14. Nikforov MA, Riblett M, Tang WH, Gratchouck V, Hari M, Fernandez Y, Verhaegen M, Jakubowiak A, and Soengas MS. Selective activation of tumor cell death upon proteasome inhibition driven by MYC-dependent activation of NOXA. [Submitted to Cancer Cell]